Blinatumomab Consolidation in Real World (NCT07117136) | Clinical Trial Compass
RecruitingNot Applicable
Blinatumomab Consolidation in Real World
United States200 participantsStarted 2025-08-28
Plain-language summary
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients
Exclusion Criteria:
* N/A
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is described as a 'real world' study of blinatumomab consolidation — does that mean it's observational rather than a randomized trial, and if so, what does that mean for my treatment choices and whether I'd receive blinatumomab regardless of whether I join?
2The primary outcome being measured is the percentage of patients who achieve complete remission — given where I am in my treatment right now, is consolidation with blinatumomab something that would even be on the table for me, and does this study align with the stage of B-cell ALL I have?
3Since this trial is listed as phase 'NA,' which often applies to observational or registry-type studies, does that mean there's already enough real-world or clinical data on blinatumomab's safety profile that my doctor feels comfortable discussing its known risks and side effects with me in detail?
4How does participating in this observational study affect my day-to-day care — would I need extra hospital visits, additional monitoring, or data collection appointments beyond what my standard treatment would already require?
5Are there standard consolidation treatment options outside of this trial that my doctor would consider for my specific situation, and how would blinatumomab compare to those alternatives in terms of what's currently known about outcomes for someone with my type of B-cell ALL?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percentage of participants with complete remission
Timeframe: 5 years or e.g., 1 year after closure of study